carvedilol has been researched along with Left Ventricular Dysfunction in 157 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 9.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF)." | 9.20 | Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure. ( Doğan, A; Erdoğan, D; Karabacak, M; Özaydın, M; Tayyar, Ş, 2015) |
| " The present study investigated the possible protective role of carvedilol on ADR-induced left ventricular dysfunction in children with ALL." | 9.16 | Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. ( El-Hawary, EE; El-Shanshory, MR; El-Shitany, NA; Tolba, OA, 2012) |
| "Background Carvedilol may reduce the severity of central sleep apnea (CSA) in patients with chronic heart failure (CHF)." | 9.14 | Carvedilol reduces the severity of central sleep apnea in chronic heart failure. ( Kadota, J; Kawano, Y; Tamura, A, 2009) |
| "We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)." | 9.12 | Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006) |
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 9.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction." | 9.12 | Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007) |
| " Before the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)-a multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <==0." | 9.11 | Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). ( Colucci, WS, 2004) |
| "The purpose of this study was to investigate the effects of carvedilol on diastolic function (DF) in heart failure patients with preserved left ventricular (LV) systolic function and abnormal DF." | 9.11 | Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). ( Andersson, B; Bergström, A; Dahlström, U; Edner, M; Nylander, E; Persson, H, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 9.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "Carvedilol is a beta-blocking agent with antioxidant properties that has been shown to improve survival in chronic heart failure (CHF)." | 9.11 | Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. ( Abergel, E; Berdeaux, A; Cohen-Solal, A; Le Guludec, D; Merlet, P; Rouzet, F; Syrota, A, 2005) |
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 9.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 9.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "The aim of the study was to assess the effects of carvedilol, a vasodilating nonselective beta-blocker, on the indexes of left ventricular remodeling after acute myocardial infarction in those with left ventricular dysfunction." | 9.09 | Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. ( Basu, S; Kinsey, C; Lahiri, A; Schaeffer, S; Senior, R, 1999) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 9.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "In patients with chronic heart failure, the use of carvedilol therapy induces clinical and hemodynamic improvement." | 9.09 | Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. ( Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Mortara, A; Opasich, C; Pinna, GD; Riccardi, G, 2000) |
| "In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions." | 9.09 | Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. ( Dargie, HJ, 2001) |
| "Although neurohormonal status has known prognostic significance in heart failure, the predictive power of either N-BNP or adrenomedullin in chronic ischemic LV dysfunction has not been previously reported." | 9.09 | Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; MacMahon, S; Murphy, J; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 2001) |
| "A number of studies showed the improvement in left ventricular (LV) function and clinical outcome that carvedilol produces in patients with severe congestive heart failure (CHF)." | 9.09 | [Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction]. ( Cioffi, G; Stefenelli, C, 2001) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 8.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure." | 8.82 | New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 7.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "The IMPACT-HF trial demonstrated that carvedilol use at the time of heart failure (HF) hospital discharge significantly increased 90-day postdischarge treatment rates." | 7.74 | Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, C; Young, JB, 2007) |
| "Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients." | 7.73 | Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005) |
| " In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated." | 7.73 | Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? ( Bobbio, M; Catalano, E; Ferrua, S; Grassi, G; Massobrio, N; Pinach, S; Rossi, C; Trevi, GP; Veglio, M, 2005) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 7.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| "This study assessed the effects of combination therapy with simvastatin and carvedilol on clinical outcome in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI)." | 7.73 | Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. ( Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, SR; Park, HW; Park, JC; Yun, NS, 2006) |
| "Despite less than target doses in most patients, a favorable effect of carvedilol on functional class in patients with severe congestive heart failure (CHF) referred for transplant was observed." | 7.70 | Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. ( Amin, H; Aminbakhsh, A; D'yachkova, Y; Ignaszweski, AP; Mortimer, S; Pamboukian, SV; Thompson, CR, 1999) |
| " Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF." | 6.82 | Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. ( Park, K; Park, TH, 2016) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 6.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction < or =40%) and reduced exercise tolerance (peak oxygen consumption <25 ml/kg/min) despite chronic (>1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue on metoprolol (n = 16, mean dosage 142+/-44 mg/day) or to cross over to maximum tolerated dosage of carvedilol (n = 14, mean dosage 74+/-23 mg/day)." | 6.69 | Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. ( Camerini, F; Ciani, F; Di Lenarda, A; Gregori, D; Klugmann, S; Mestroni, L; Muzzi, A; Pinamonti, B; Sabbadini, G; Salvatore, L; Sinagra, G, 1999) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 6.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "Carvedilol is a beta- and alpha-adrenergic-blocking drug with clinically important antiarrhythmic properties." | 6.43 | Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. ( Lukas, MA; Naccarelli, GV, 2005) |
| "We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study)." | 6.25 | Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. ( Beck, GJ; Berl, T; Chartyan, DM; Cheung, AK; Chonchol, M; Cooper, C; Henrich, WL; Himmelfarb, J; Iyengar, M; Lukas, MA; Wali, RK; Weir, MR, 2011) |
| "Carvedilol treatment for CHF patients is a highly cost-effective method of therapy in the Japanese medical environment." | 5.32 | Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. ( Inomata, T; Izumi, T; Kobayashi, M, 2004) |
| "Carvedilol was started at a dose of 3." | 5.31 | [Reversibility of left ventricular dysfunction in elderly patients with dilated cardiomyopathy undergoing treatment with carvedilol. Report of a case]. ( Cioffi, G; Stefenelli, C, 2001) |
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 5.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients." | 5.22 | Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. ( Borley, A; Broom, A; Collins, G; Guppy, A; Hall, P; Henriksen, PA; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Radford, J; Rowntree, C; Scott, F, 2022) |
| "It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF)." | 5.20 | Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure. ( Doğan, A; Erdoğan, D; Karabacak, M; Özaydın, M; Tayyar, Ş, 2015) |
| " The present study investigated the possible protective role of carvedilol on ADR-induced left ventricular dysfunction in children with ALL." | 5.16 | Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. ( El-Hawary, EE; El-Shanshory, MR; El-Shitany, NA; Tolba, OA, 2012) |
| "Background Carvedilol may reduce the severity of central sleep apnea (CSA) in patients with chronic heart failure (CHF)." | 5.14 | Carvedilol reduces the severity of central sleep apnea in chronic heart failure. ( Kadota, J; Kawano, Y; Tamura, A, 2009) |
| "beta-adrenergic receptor antagonism with drugs like carvedilol slows the progression of heart failure by an undefined mechanism." | 5.12 | The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. ( Bocchi, EA; Chizzola, PR; Gonçalves de Freitas, HF; Mansur, JA; Marinho, NV; Meneghetti, JC, 2006) |
| "The effect of the beta-blocker, carvedilol, and/or ACEI on ventricular function in patients with muscular dystrophy was studied." | 5.12 | Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. ( Ishigaki, K; Kajimoto, H; Nakanishi, T; Nakazawa, M; Okumura, K; Osawa, M; Saito, K; Tomimatsu, H, 2006) |
| "We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)." | 5.12 | Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006) |
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 5.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction." | 5.12 | Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007) |
| " Before the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)-a multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <==0." | 5.11 | Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). ( Colucci, WS, 2004) |
| "The purpose of this study was to investigate the effects of carvedilol on diastolic function (DF) in heart failure patients with preserved left ventricular (LV) systolic function and abnormal DF." | 5.11 | Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). ( Andersson, B; Bergström, A; Dahlström, U; Edner, M; Nylander, E; Persson, H, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 5.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "Carvedilol is a beta-blocking agent with antioxidant properties that has been shown to improve survival in chronic heart failure (CHF)." | 5.11 | Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. ( Abergel, E; Berdeaux, A; Cohen-Solal, A; Le Guludec, D; Merlet, P; Rouzet, F; Syrota, A, 2005) |
| "We performed a prospective, randomized, double-blind, placebo-controlled study of carvedilol effects in children with severe, chronic heart failure (HF), despite the use of conventional therapy." | 5.10 | Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. ( Alcides Bocchi, E; Azeka, E; Franchini Ramires, JA; Valler, C, 2002) |
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 5.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 5.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "The aim of the study was to assess the effects of carvedilol, a vasodilating nonselective beta-blocker, on the indexes of left ventricular remodeling after acute myocardial infarction in those with left ventricular dysfunction." | 5.09 | Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. ( Basu, S; Kinsey, C; Lahiri, A; Schaeffer, S; Senior, R, 1999) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 5.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "In patients with chronic heart failure, the use of carvedilol therapy induces clinical and hemodynamic improvement." | 5.09 | Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. ( Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Mortara, A; Opasich, C; Pinna, GD; Riccardi, G, 2000) |
| "Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernating myocardium." | 5.09 | The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. ( Cleland, JG; Coats, A; Cowley, A; Lahiri, A; MacFarlane, P; Murray, G; Pennel, D; Ray, S, 1999) |
| "In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions." | 5.09 | Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. ( Dargie, HJ, 2001) |
| "Although neurohormonal status has known prognostic significance in heart failure, the predictive power of either N-BNP or adrenomedullin in chronic ischemic LV dysfunction has not been previously reported." | 5.09 | Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; MacMahon, S; Murphy, J; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 2001) |
| "We retrospectively evaluated patients entered into the Multicenter Oral Carvedilol Heart failure Assessment (MOCHA) trial, a 6-month, double-blind, randomized, placebo-controlled, multicenter, dose-response evaluation of carvedilol in patients with chronic stable symptomatic heart failure." | 5.09 | Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. ( Bristow, MR; Lindenfeld, J; Lowes, BD; Robertson, AD, 2001) |
| "A number of studies showed the improvement in left ventricular (LV) function and clinical outcome that carvedilol produces in patients with severe congestive heart failure (CHF)." | 5.09 | [Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction]. ( Cioffi, G; Stefenelli, C, 2001) |
| " Studies investigating any of three beta blockers (carvedilol, bisoprolol, and extended release metoprolol succinate) which are known to be effective in adult patients with heart failure were included." | 4.91 | Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies. ( Cho, MJ; Jung Kwak, M; Kim, HY; Kim, YM; Lee, HD; Lim, RK; Park, KH, 2015) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 4.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure." | 4.82 | New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003) |
| "Patients with chronic heart failure due to left ventricular systolic dysfunction of ischemic or nonischemic etiology have shown improvement in morbidity and mortality with carvedilol therapy." | 4.81 | Carvedilol in the failing heart. ( Gilbert, EM; Lombardi, WL, 2001) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 3.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "The IMPACT-HF trial demonstrated that carvedilol use at the time of heart failure (HF) hospital discharge significantly increased 90-day postdischarge treatment rates." | 3.74 | Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, C; Young, JB, 2007) |
| "Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients." | 3.73 | Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005) |
| "We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)." | 3.73 | Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005) |
| " In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated." | 3.73 | Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? ( Bobbio, M; Catalano, E; Ferrua, S; Grassi, G; Massobrio, N; Pinach, S; Rossi, C; Trevi, GP; Veglio, M, 2005) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 3.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| "This study assessed the effects of combination therapy with simvastatin and carvedilol on clinical outcome in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI)." | 3.73 | Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. ( Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, SR; Park, HW; Park, JC; Yun, NS, 2006) |
| " The normalization was predicted by the nonischemic etiology of CHF, arterial hypertension, absence of diabetes mellitus, carvedilol therapy, and the dose of carvedilol." | 3.72 | Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2004) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| " For all these reasons, the CAPRICORN trial of carvedilol in post-MI left ventricular dysfunction was an important and eagerly awaited trial, which could show that carvedilol treatment post-MI on top of the so-called modern post-MI therapy reduces mortality." | 3.71 | [Beta blockers in post-infarction state]. ( Schultheiss, HP; Tschöpe, C, 2002) |
| "The CAPRICORN and COPERNICUS studies have confirmed the significance of betablocker treatment with carvedilol for indications which this medication did not yet possess: post-infarction with left ventricular dysfunction with or without clinical signs, and stable severe cardiac insufficiency." | 3.71 | [CAPRICORN and COPERINUS studies]. ( Juillière, Y, 2002) |
| "To evaluate the efficacy of carvedilol for left ventricular dysfunction in Duchenne muscular dystrophy (DMD), we enrolled 8 patients with DMD who had elevated plasma atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP), and a low ejection fraction (EF < 40%) in echocardiography." | 3.71 | [Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy]. ( Matsumura, T; Miyai, I; Nozaki, S; Saito, T; Shinno, S, 2001) |
| "To examine the ability of myocardial contractile reserve (MCR) assessment to predict the improvement of left ventricular ejection fraction with treatment by carvedilol, a prospective study was undertaken in 85 patients with chronic heart failure and left ventricular ejection fraction < 45%." | 3.71 | Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. ( Bellorini, M; Desnos, M; Fulla, Y; Funck, F; Guillard, N; Hagege, A; Jourdain, P; Loiret, J; Thebault, B, 2002) |
| "Despite less than target doses in most patients, a favorable effect of carvedilol on functional class in patients with severe congestive heart failure (CHF) referred for transplant was observed." | 3.70 | Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. ( Amin, H; Aminbakhsh, A; D'yachkova, Y; Ignaszweski, AP; Mortimer, S; Pamboukian, SV; Thompson, CR, 1999) |
| " Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF." | 2.82 | Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. ( Park, K; Park, TH, 2016) |
| "The use of antracycline (ANT) in breast cancer has been associated with adverse cardiac events." | 2.79 | Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. ( Bugra, Z; Ciftci, R; Cizgici, AY; Elitok, A; Kilic, L; Mercanoglu, F; Oflaz, H; Oncul, A; Oz, F; Sen, F, 2014) |
| "Cardiac resynchronization therapy (CRT), combined with optimal medical therapy (OMT), is an established treatment for patients with advanced chronic heart failure (ACHF)." | 2.76 | CArdiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study. ( Bisetti, S; Cantù, F; De Luca, A; De Santo, T; Gavazzi, A; Gori, M; Grosu, A; Iacovoni, A; Senni, M, 2011) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 2.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "Carvedilol treatment can improve cardiac function, symptoms, and cardiac sympathetic nerve activity in patients with DCM to a similar extent as metoprolol treatment." | 2.71 | Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. ( Adachi, H; Hoshizaki, H; Isobe, N; Naito, S; Oshima, S; Seki, R; Taniguchi, K; Toyama, T, 2003) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation." | 2.71 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. ( Charlesworth, A; Cleland, J; Hanrath, P; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction < or =40%) and reduced exercise tolerance (peak oxygen consumption <25 ml/kg/min) despite chronic (>1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue on metoprolol (n = 16, mean dosage 142+/-44 mg/day) or to cross over to maximum tolerated dosage of carvedilol (n = 14, mean dosage 74+/-23 mg/day)." | 2.69 | Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. ( Camerini, F; Ciani, F; Di Lenarda, A; Gregori, D; Klugmann, S; Mestroni, L; Muzzi, A; Pinamonti, B; Sabbadini, G; Salvatore, L; Sinagra, G, 1999) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 2.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | 2.48 | β-blockers in stage B: a precursor of heart failure. ( Francis, GS; Sarraf, M, 2012) |
| "Advances in cancer treatment have greatly improved survival rates of children with cancer." | 2.48 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. ( Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL, 2012) |
| "Carvedilol is a beta- and alpha-adrenergic-blocking drug with clinically important antiarrhythmic properties." | 2.43 | Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. ( Lukas, MA; Naccarelli, GV, 2005) |
| "Carvedilol is a third-generation beta(1)- and beta(2)-blocker that also possesses alpha(1)-adrenergic-blocking properties." | 2.43 | Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. ( Fonarow, GC, 2006) |
| " We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure." | 2.42 | Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? ( Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003) |
| "Carvedilol is an inherently long-acting beta-blocker while the duration of beta blockade for metoprolol is dependent on the salt and formulation, which is used." | 2.42 | Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. ( Talbert, RL, 2004) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Severe aortic regurgitation was induced by retrograde puncture of the aortic valve leaflets under sonographic guidance in 12-week-old male C57BL/6J mice." | 1.42 | Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention. ( Ge, J; Qian, J; Wang, X; Wu, J; You, J; Zhu, D; Zou, Y, 2015) |
| "After appropriate pharmacologic treatment of her hyperthyroidism, she had complete resolution of her cardiomyopathy." | 1.40 | Biventricular Takotsubo cardiomyopathy in Graves hyperthyroidism. ( Perkins, MJ; Schachter, DT, 2014) |
| "Carvedilol was initiated at a mean dose of 0." | 1.39 | Clinical and echocardiographic outcome in patients receiving carvedilol for treatment of dilated cardiomyopathy. ( Anil, OM; Juneja, R; Saxena, A, 2013) |
| "Carvedilol was initiated 3 days after admission (median); 594 patients (97%) were discharged alive, 27 (5%) without beta-blockers." | 1.36 | Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry. ( Alhama, M; Barrueco, N; Castillo, I; Datino, T; Fernández-Avilés, F; Martínez-Sellés, M, 2010) |
| "Heart failure is correlated with attenuation of parasympathetic nervous function and enhanced sympathetic activity." | 1.33 | Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. ( Kang, XQ; Li, M; Lu, J; Xu, XL; Yu, XJ; Zang, WJ, 2006) |
| " Carvedilol is excreted by the liver and there were minimal fluctuations between hemodialysis, so, theoretically, drug dosage of the agent should be the same as in non-hemodialysis patients." | 1.33 | [Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction]. ( Ishii, A; Nakano, H; Nakayama, M; Takeguchi, F, 2006) |
| "Carvedilol treatment for CHF patients is a highly cost-effective method of therapy in the Japanese medical environment." | 1.32 | Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. ( Inomata, T; Izumi, T; Kobayashi, M, 2004) |
| "Carvedilol is a nonselective beta-adrenoceptor antagonist with additional alpha 1-receptor-blocking properties." | 1.31 | [Hormonal hyperactivity in heart failure. Differences in beta blockers]. ( Beuckelmann, DJ, 2002) |
| "Carvedilol was started at a dose of 3." | 1.31 | [Reversibility of left ventricular dysfunction in elderly patients with dilated cardiomyopathy undergoing treatment with carvedilol. Report of a case]. ( Cioffi, G; Stefenelli, C, 2001) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (5.73) | 18.2507 |
| 2000's | 109 (69.43) | 29.6817 |
| 2010's | 36 (22.93) | 24.3611 |
| 2020's | 3 (1.91) | 2.80 |
| Authors | Studies |
|---|---|
| Henriksen, PA | 1 |
| Hall, P | 1 |
| Oikonomidou, O | 1 |
| MacPherson, IR | 1 |
| Maclean, M | 1 |
| Lewis, S | 1 |
| McVicars, H | 1 |
| Broom, A | 1 |
| Scott, F | 1 |
| McKay, P | 1 |
| Borley, A | 1 |
| Rowntree, C | 1 |
| Lord, S | 1 |
| Collins, G | 1 |
| Radford, J | 1 |
| Guppy, A | 1 |
| Payne, JR | 1 |
| Newby, DE | 1 |
| Mills, NL | 1 |
| Lang, NN | 1 |
| McCutcheon, K | 1 |
| Dickens, C | 1 |
| van Pelt, J | 1 |
| Dix-Peek, T | 1 |
| Grinter, S | 1 |
| McCutcheon, L | 1 |
| Patel, A | 1 |
| Hale, M | 1 |
| Tsabedze, N | 1 |
| Vachiat, A | 1 |
| Zachariah, D | 1 |
| Duarte, R | 1 |
| Janssens, S | 1 |
| Manga, P | 1 |
| Beiranvand, E | 1 |
| Ostad, SN | 1 |
| Ardakani, EM | 1 |
| Torkashvand, F | 1 |
| Sardari, S | 1 |
| Vaziri, B | 1 |
| Jones, L | 1 |
| Isenmen, H | 1 |
| Jhorawat, R | 1 |
| Kumari, S | 1 |
| Varma, SC | 1 |
| Rohit, MK | 1 |
| Narula, N | 1 |
| Suri, V | 1 |
| Malhotra, P | 1 |
| Jain, S | 1 |
| Guglin, M | 1 |
| Munster, P | 1 |
| Fink, A | 1 |
| Krischer, J | 1 |
| Bayoumi, AS | 1 |
| Park, KM | 1 |
| Wang, Y | 2 |
| Teoh, JP | 1 |
| Aonuma, T | 1 |
| Tang, Y | 1 |
| Su, H | 1 |
| Weintraub, NL | 1 |
| Kim, IM | 1 |
| Abuosa, AM | 1 |
| Elshiekh, AH | 1 |
| Qureshi, K | 1 |
| Abrar, MB | 1 |
| Kholeif, MA | 1 |
| Kinsara, AJ | 1 |
| Andejani, A | 1 |
| Ahmed, AH | 1 |
| Cleland, JGF | 1 |
| Saxena, A | 1 |
| Anil, OM | 1 |
| Juneja, R | 1 |
| Fonarow, G | 2 |
| Cannon, C | 1 |
| Epstein, A | 1 |
| Smiseth, OA | 1 |
| Edvardsen, T | 1 |
| Skulstad, H | 1 |
| Bosch, X | 2 |
| Rovira, M | 2 |
| Sitges, M | 2 |
| Domènech, A | 2 |
| Ortiz-Pérez, JT | 1 |
| de Caralt, TM | 2 |
| Morales-Ruiz, M | 2 |
| Perea, RJ | 2 |
| Monzó, M | 2 |
| Esteve, J | 2 |
| Yanagihara, K | 1 |
| Kinugasa, Y | 1 |
| Sugihara, S | 1 |
| Hirai, M | 1 |
| Yamada, K | 1 |
| Ishida, K | 1 |
| Kato, M | 1 |
| Yamamoto, K | 1 |
| Kaya, MG | 1 |
| Sarli, B | 1 |
| Akpek, M | 1 |
| Kaya, EG | 1 |
| Yarlioglues, M | 1 |
| Topsakal, R | 1 |
| Lam, YY | 1 |
| Elitok, A | 1 |
| Oz, F | 1 |
| Cizgici, AY | 1 |
| Kilic, L | 1 |
| Ciftci, R | 1 |
| Sen, F | 1 |
| Bugra, Z | 1 |
| Mercanoglu, F | 1 |
| Oncul, A | 1 |
| Oflaz, H | 1 |
| Perkins, MJ | 1 |
| Schachter, DT | 1 |
| Tanaka, H | 2 |
| Matsumoto, K | 2 |
| Sawa, T | 1 |
| Miyoshi, T | 2 |
| Motoji, Y | 1 |
| Imanishi, J | 1 |
| Mochizuki, Y | 1 |
| Tatsumi, K | 2 |
| Hirata, K | 2 |
| Li, X | 1 |
| Matta, SM | 1 |
| Sullivan, RD | 1 |
| Bahouth, SW | 1 |
| Cho, MJ | 1 |
| Lim, RK | 1 |
| Jung Kwak, M | 1 |
| Park, KH | 1 |
| Kim, HY | 1 |
| Kim, YM | 1 |
| Lee, HD | 1 |
| Karabacak, M | 1 |
| Doğan, A | 1 |
| Tayyar, Ş | 1 |
| Özaydın, M | 1 |
| Erdoğan, D | 1 |
| Bagriy, AE | 1 |
| Schukina, EV | 1 |
| Samoilova, OV | 1 |
| Pricolota, OA | 1 |
| Malovichko, SI | 1 |
| Pricolota, AV | 1 |
| Bagriy, EA | 1 |
| Wang, X | 1 |
| Wu, J | 2 |
| Zhu, D | 1 |
| You, J | 1 |
| Zou, Y | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Shyamali, NL | 1 |
| Ranawaka, H | 1 |
| Dahle, GO | 1 |
| Salminen, PR | 1 |
| Moen, CA | 1 |
| Eliassen, F | 1 |
| Nygreen, E | 1 |
| Kytö, V | 1 |
| Saukko, P | 1 |
| Haaverstad, R | 1 |
| Matre, K | 1 |
| Grong, K | 1 |
| Armenian, SH | 1 |
| Hudson, MM | 1 |
| Chen, MH | 1 |
| Colan, SD | 1 |
| Lindenfeld, L | 1 |
| Mills, G | 1 |
| Siyahian, A | 1 |
| Gelehrter, S | 1 |
| Dang, H | 1 |
| Hein, W | 1 |
| Green, DM | 1 |
| Robison, LL | 1 |
| Wong, FL | 1 |
| Douglas, PS | 1 |
| Bhatia, S | 1 |
| Park, K | 1 |
| Park, TH | 1 |
| Mano, A | 1 |
| Nakatani, T | 1 |
| Oda, N | 1 |
| Kato, T | 1 |
| Niwaya, K | 1 |
| Tagusari, O | 1 |
| Nakajima, H | 1 |
| Funatsu, T | 1 |
| Hashimoto, S | 1 |
| Komamura, K | 1 |
| Hanatani, A | 1 |
| Ueda, IH | 1 |
| Kitakaze, M | 1 |
| Kobayashi, J | 1 |
| Yagihara, T | 1 |
| Kitamura, S | 1 |
| Carter, NJ | 1 |
| Keating, GM | 1 |
| Nessler, J | 2 |
| Nessler, B | 2 |
| Kitliński, M | 2 |
| Stepniewski, M | 2 |
| Piwowarska, W | 2 |
| Cadrin-Tourigny, J | 1 |
| Fournier, A | 1 |
| Andelfinger, G | 1 |
| Khairy, P | 1 |
| Tamura, A | 1 |
| Kawano, Y | 1 |
| Kadota, J | 1 |
| Altenberger, H | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Frishman, WH | 1 |
| Henderson, LS | 1 |
| Lukas, MA | 5 |
| Allen LaPointe, NM | 1 |
| Zhou, Y | 1 |
| Stafford, JA | 1 |
| Hernandez, AF | 1 |
| Kramer, JM | 1 |
| Anstrom, KJ | 1 |
| Adams, KF | 2 |
| Ito, T | 1 |
| Kawanishi, Y | 1 |
| Futai, R | 1 |
| Terasaki, F | 1 |
| Kitaura, Y | 1 |
| Chandar, S | 1 |
| Yeo, LS | 1 |
| Leimena, C | 1 |
| Tan, JC | 1 |
| Xiao, XH | 1 |
| Nikolova-Krstevski, V | 1 |
| Yasuoka, Y | 1 |
| Gardiner-Garden, M | 1 |
| Kesteven, S | 1 |
| Karlsdotter, L | 1 |
| Natarajan, S | 1 |
| Carlton, A | 1 |
| Rainer, S | 1 |
| Feneley, MP | 1 |
| Fatkin, D | 1 |
| Martínez-Sellés, M | 1 |
| Datino, T | 1 |
| Alhama, M | 1 |
| Barrueco, N | 1 |
| Castillo, I | 1 |
| Fernández-Avilés, F | 1 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Metra, M | 3 |
| Covolo, L | 1 |
| Pezzali, N | 1 |
| Zacà, V | 1 |
| Bugatti, S | 1 |
| Lombardi, C | 1 |
| Bettari, L | 1 |
| Romeo, A | 1 |
| Gelatti, U | 1 |
| Giubbini, R | 2 |
| Donato, F | 1 |
| Dei Cas, L | 2 |
| Petko, C | 1 |
| Minich, LL | 1 |
| Everitt, MD | 1 |
| Holubkov, R | 1 |
| Shaddy, RE | 3 |
| Tani, LY | 2 |
| Remme, WJ | 3 |
| Dabrowski, R | 1 |
| Pedzich-Placha, E | 1 |
| Wali, RK | 1 |
| Iyengar, M | 1 |
| Beck, GJ | 1 |
| Chartyan, DM | 1 |
| Chonchol, M | 1 |
| Cooper, C | 1 |
| Himmelfarb, J | 1 |
| Weir, MR | 1 |
| Berl, T | 1 |
| Henrich, WL | 1 |
| Cheung, AK | 1 |
| Hiraishi, M | 1 |
| Tsuji, T | 1 |
| Kaneko, A | 1 |
| Ryo, K | 1 |
| Yamawaki, K | 1 |
| Fukuda, Y | 1 |
| Norisada, K | 1 |
| Kawai, H | 1 |
| Ortiz, JT | 1 |
| Grosu, A | 1 |
| Senni, M | 1 |
| Iacovoni, A | 1 |
| Gori, M | 1 |
| Cantù, F | 1 |
| Bisetti, S | 1 |
| De Santo, T | 1 |
| De Luca, A | 1 |
| Gavazzi, A | 2 |
| Sarraf, M | 1 |
| Francis, GS | 1 |
| El-Shitany, NA | 1 |
| Tolba, OA | 1 |
| El-Shanshory, MR | 1 |
| El-Hawary, EE | 1 |
| Harake, D | 1 |
| Franco, VI | 1 |
| Henkel, JM | 1 |
| Miller, TL | 1 |
| Lipshultz, SE | 1 |
| Williams, RV | 1 |
| Otterstad, JE | 1 |
| Ford, I | 1 |
| Schultheiss, HP | 2 |
| Tschöpe, C | 1 |
| Beuckelmann, DJ | 1 |
| Azeka, E | 1 |
| Franchini Ramires, JA | 1 |
| Valler, C | 1 |
| Alcides Bocchi, E | 1 |
| Isnard, R | 1 |
| Podbregar, M | 1 |
| Voga, G | 1 |
| Nodari, S | 1 |
| Parrinello, G | 1 |
| Manca, C | 1 |
| Al-Nasser, F | 1 |
| Yousufuddin, M | 1 |
| Al-Nozha, F | 1 |
| Anker, SD | 1 |
| Coats, AJ | 4 |
| Piepoli, MF | 1 |
| Ponikowski, PP | 1 |
| Etheridge, SP | 1 |
| Cleland, JG | 5 |
| Pennell, DJ | 3 |
| Ray, SG | 2 |
| Macfarlane, PW | 1 |
| Murray, GD | 2 |
| Mule, JD | 1 |
| Vered, Z | 1 |
| Lahiri, A | 5 |
| Maunoury, C | 1 |
| Acar, P | 1 |
| Sidi, D | 1 |
| Toyama, T | 2 |
| Hoshizaki, H | 1 |
| Seki, R | 1 |
| Isobe, N | 1 |
| Adachi, H | 1 |
| Naito, S | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Sackner-Bernstein, JD | 1 |
| Palazzuoli, A | 1 |
| Carrera, A | 1 |
| Calabria, P | 1 |
| Puccetti, L | 1 |
| Pastrorelli, M | 1 |
| Pasqui, AL | 1 |
| Auteri, A | 1 |
| Bruni, F | 1 |
| Inomata, T | 1 |
| Izumi, T | 1 |
| Kobayashi, M | 1 |
| Massie, BM | 1 |
| Bristow, MR | 2 |
| Feldman, AM | 1 |
| Goldstein, S | 1 |
| Fukuchi, K | 1 |
| Yasumura, Y | 1 |
| Kiso, K | 1 |
| Hayashida, K | 1 |
| Miyatake, K | 1 |
| Ishida, Y | 1 |
| Colucci, WS | 2 |
| Udelson, JE | 1 |
| Bergström, A | 1 |
| Andersson, B | 1 |
| Edner, M | 1 |
| Nylander, E | 1 |
| Persson, H | 1 |
| Dahlström, U | 1 |
| Komajda, M | 2 |
| Lutiger, B | 1 |
| Madeira, H | 1 |
| Thygesen, K | 1 |
| Bobbio, M | 2 |
| Hildebrandt, P | 1 |
| Jaarsma, W | 1 |
| Riegger, G | 1 |
| Rydén, L | 1 |
| Scherhag, A | 1 |
| Soler-Soler, J | 1 |
| Cioffi, G | 4 |
| Stefenelli, C | 4 |
| Tarantini, L | 2 |
| Opasich, C | 3 |
| Bellenger, NG | 1 |
| Rajappan, K | 1 |
| Rahman, SL | 1 |
| Raval, U | 2 |
| Webster, J | 2 |
| Kotlyar, E | 1 |
| Hayward, CS | 1 |
| Keogh, AM | 1 |
| Feneley, M | 1 |
| Macdonald, PS | 1 |
| Abdulla, J | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 2 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Talbert, RL | 1 |
| Kasama, S | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Tange, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| Swedberg, K | 1 |
| Olsson, LG | 1 |
| Charlesworth, A | 1 |
| Cleland, J | 1 |
| Hanrath, P | 1 |
| Poole-Wilson, P | 1 |
| Naccarelli, GV | 2 |
| Reiffel, JA | 1 |
| Nul, D | 1 |
| Zambrano, C | 1 |
| Diaz, A | 1 |
| Ferrante, D | 1 |
| Varini, S | 1 |
| Soifer, S | 1 |
| Grancelli, H | 1 |
| Doval, H | 1 |
| Sun, YL | 1 |
| Hu, SJ | 1 |
| Wang, LH | 1 |
| Hu, Y | 1 |
| Zhou, JY | 1 |
| Ferrua, S | 1 |
| Catalano, E | 1 |
| Grassi, G | 1 |
| Massobrio, N | 1 |
| Pinach, S | 1 |
| Rossi, C | 1 |
| Veglio, M | 1 |
| Trevi, GP | 1 |
| Kaandorp, TA | 1 |
| Lamb, HJ | 1 |
| Bax, JJ | 1 |
| Boersma, E | 1 |
| Viergever, EP | 1 |
| van der Wall, EE | 1 |
| de Roos, A | 1 |
| Cohen-Solal, A | 1 |
| Rouzet, F | 1 |
| Berdeaux, A | 1 |
| Le Guludec, D | 1 |
| Abergel, E | 1 |
| Syrota, A | 1 |
| Merlet, P | 1 |
| Chizzola, PR | 1 |
| Gonçalves de Freitas, HF | 1 |
| Marinho, NV | 1 |
| Mansur, JA | 1 |
| Meneghetti, JC | 1 |
| Bocchi, EA | 1 |
| De Feo, S | 1 |
| Pulignano, G | 1 |
| Del Sindaco, D | 1 |
| Paperini, L | 1 |
| Genovesi, A | 1 |
| Carluccio, M | 1 |
| Tölg, R | 1 |
| Witt, M | 1 |
| Schwarz, B | 1 |
| Kurz, T | 1 |
| Kurowski, V | 1 |
| Hartmann, F | 1 |
| Geist, V | 1 |
| Richardt, G | 1 |
| Paraskevaidis, IA | 1 |
| Tsiapras, D | 2 |
| Karavolias, G | 1 |
| Adamopoulos, S | 1 |
| Dodouras, T | 2 |
| Cokkinos, P | 1 |
| Kremastinos, DT | 2 |
| Xu, XL | 1 |
| Zang, WJ | 1 |
| Lu, J | 1 |
| Kang, XQ | 1 |
| Li, M | 1 |
| Yu, XJ | 1 |
| Nakayama, M | 1 |
| Ishii, A | 1 |
| Takeguchi, F | 1 |
| Nakano, H | 1 |
| Kajimoto, H | 1 |
| Ishigaki, K | 1 |
| Okumura, K | 1 |
| Tomimatsu, H | 1 |
| Nakazawa, M | 1 |
| Saito, K | 1 |
| Osawa, M | 1 |
| Nakanishi, T | 1 |
| Bozić, I | 1 |
| Fabijanić, D | 1 |
| Carević, V | 1 |
| Polić, S | 1 |
| Hong, YJ | 1 |
| Jeong, MH | 1 |
| Hwang, SH | 1 |
| Yun, NS | 1 |
| Lee, SR | 1 |
| Hong, SN | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Packer, M | 1 |
| Tenero, DM | 1 |
| Baidoo, CA | 1 |
| Greenberg, BH | 2 |
| Korantzopoulos, P | 1 |
| Patsouras, D | 1 |
| Siogas, K | 1 |
| Fonarow, GC | 3 |
| Abraham, WT | 1 |
| Albert, NM | 2 |
| Stough, WG | 1 |
| Gheorghiade, M | 1 |
| O'Connor, CM | 1 |
| Sun, JL | 1 |
| Yancy, C | 1 |
| Young, JB | 1 |
| Doughty, RN | 1 |
| White, HD | 1 |
| Heringer-Walther, S | 1 |
| Moreira, Mda C | 1 |
| Wessel, N | 1 |
| Ventura, TM | 1 |
| Walther, T | 1 |
| Neglia, D | 1 |
| De Maria, R | 1 |
| Masi, S | 1 |
| Gallopin, M | 1 |
| Pisani, P | 1 |
| Pardini, S | 1 |
| L'abbate, A | 1 |
| Parodi, O | 1 |
| Mezzani, A | 1 |
| Corrà, U | 1 |
| Giordano, A | 1 |
| Cafagna, M | 1 |
| Adriano, EP | 1 |
| Giannuzzi, P | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Goch, JH | 1 |
| Chizyński, K | 1 |
| Paraskevaidis, I | 1 |
| Farmakis, D | 1 |
| Parissis, JT | 1 |
| Filippatos, G | 1 |
| Gandhi, PS | 1 |
| Goyal, RK | 1 |
| Jain, AR | 1 |
| Mallya, BS | 1 |
| Gupta, VM | 1 |
| Shah, DS | 1 |
| Trivedi, BR | 1 |
| Shastri, NA | 1 |
| Mehta, CB | 1 |
| Jain, KA | 1 |
| Bhavasar, NS | 1 |
| Shah, UJ | 1 |
| Heidenreich, PA | 1 |
| Gholami, P | 1 |
| Sahay, A | 1 |
| Massie, B | 1 |
| Goldstein, MK | 1 |
| Sugioka, K | 1 |
| Hozumi, T | 1 |
| Takemoto, Y | 1 |
| Ehara, S | 1 |
| Ogawa, K | 1 |
| Iwata, S | 1 |
| Oe, H | 1 |
| Matsumura, Y | 1 |
| Otsuka, R | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Mrdovic, IB | 1 |
| Savic, LZ | 1 |
| Perunicic, JP | 1 |
| Asanin, MR | 1 |
| Lasica, RM | 1 |
| Jelena, MM | 1 |
| Matic, MD | 1 |
| Vasiljevic, ZM | 1 |
| Ostojic, MC | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tavazzi, L | 1 |
| Tendera, M | 1 |
| Robertson, M | 1 |
| Dargie, HJ | 3 |
| Hamaad, A | 1 |
| Lip, GY | 1 |
| Nicholls, D | 1 |
| MacFadyen, RJ | 1 |
| Gackowski, A | 1 |
| Witte, KK | 1 |
| Clark, AL | 1 |
| Cohn, JN | 1 |
| Basu, S | 2 |
| Senior, R | 2 |
| van der Does, R | 1 |
| Bruckner, T | 1 |
| Richards, AM | 2 |
| Doughty, R | 2 |
| Nicholls, MG | 2 |
| Macmahon, S | 2 |
| Ikram, H | 1 |
| Sharpe, N | 2 |
| Espiner, EA | 2 |
| Frampton, C | 2 |
| Yandle, TG | 2 |
| Kinsey, C | 1 |
| Schaeffer, S | 1 |
| Di Lenarda, A | 1 |
| Sabbadini, G | 1 |
| Salvatore, L | 1 |
| Sinagra, G | 1 |
| Mestroni, L | 1 |
| Pinamonti, B | 1 |
| Gregori, D | 1 |
| Ciani, F | 1 |
| Muzzi, A | 1 |
| Klugmann, S | 1 |
| Camerini, F | 1 |
| Pamboukian, SV | 1 |
| Aminbakhsh, A | 1 |
| Thompson, CR | 1 |
| Amin, H | 1 |
| Mortimer, S | 1 |
| D'yachkova, Y | 1 |
| Ignaszweski, AP | 1 |
| McMurray, JJ | 1 |
| Anguita Sánchez, M | 1 |
| Davies, G | 1 |
| Burgess, M | 1 |
| Slomka, P | 1 |
| Atkinson, P | 1 |
| Eichhorn, EJ | 1 |
| Grayburn, PA | 1 |
| Capomolla, S | 1 |
| Febo, O | 1 |
| Gnemmi, M | 1 |
| Riccardi, G | 1 |
| Caporotondi, A | 1 |
| Mortara, A | 1 |
| Pinna, GD | 1 |
| Cobelli, F | 1 |
| Pennel, D | 1 |
| Ray, S | 1 |
| Murray, G | 1 |
| MacFarlane, P | 1 |
| Cowley, A | 1 |
| Coats, A | 1 |
| Frantz, RP | 1 |
| Guazzi, M | 1 |
| Agostoni, PG | 1 |
| Murphy, J | 1 |
| Coutinho, J | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Matsumoto, T | 2 |
| Maeda, K | 1 |
| Mabuchi, N | 1 |
| Hayashi, M | 1 |
| Tsutsui, T | 1 |
| Ohnishi, M | 1 |
| Sawaki, M | 1 |
| Fujii, M | 1 |
| Yamamoto, T | 1 |
| Horie, H | 1 |
| Sugimoto, Y | 1 |
| Kinoshita, M | 1 |
| Joglar, JA | 1 |
| Acusta, AP | 1 |
| Shusterman, NH | 1 |
| Ramaswamy, K | 1 |
| Kowal, RC | 1 |
| Barbera, SJ | 1 |
| Hamdan, MH | 1 |
| Page, RL | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Lindenfeld, J | 1 |
| Robertson, AD | 1 |
| Lowes, BD | 1 |
| Vasil'ev, AP | 1 |
| Strel'tsova, NN | 1 |
| Gorbunova, TIu | 1 |
| Mal'tseva, IA | 1 |
| Zykova, EL | 1 |
| Lombardi, WL | 1 |
| Gilbert, EM | 1 |
| Juillière, Y | 1 |
| Comin-Colet, J | 1 |
| Sánchez-Corral, MA | 1 |
| Manito, N | 1 |
| Gómez-Hospital, JA | 1 |
| Roca, J | 1 |
| Fernández-Nofrerias, E | 1 |
| Valdovinos, P | 1 |
| Esplugas, E | 1 |
| Saito, T | 1 |
| Matsumura, T | 1 |
| Miyai, I | 1 |
| Nozaki, S | 1 |
| Shinno, S | 1 |
| Jourdain, P | 1 |
| Funck, F | 1 |
| Fulla, Y | 1 |
| Hagege, A | 1 |
| Bellorini, M | 1 |
| Guillard, N | 1 |
| Loiret, J | 1 |
| Thebault, B | 1 |
| Desnos, M | 1 |
| Gardner, RS | 1 |
| McGowan, J | 1 |
| McDonagh, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy[NCT06103279] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies[NCT01110824] | Phase 3 | 90 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial[NCT02717507] | Phase 2 | 196 participants (Actual) | Interventional | 2016-04-04 | Active, not recruiting | ||
| Comparative Effects of Nebivolol and Carvedilol on Diastolic Function of the Left Ventricle in the Elderly Heart Failure Patients With Preserved Ejection Fraction: Study Protocol for a Randomized Controlled Trial[NCT02619526] | 62 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | |||
| The Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction (Biomolecular and Clinical Study on IL-6, TNF-α, NT-ProBNP, MDA, LVEF, 6MWT, and KCCQ)[NCT05179070] | Phase 4 | 26 participants (Anticipated) | Interventional | 2021-09-10 | Recruiting | ||
| A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)[NCT02354573] | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients[NCT00344513] | Phase 4 | 50,000 participants | Interventional | 2002-12-16 | Completed | ||
| Clinical Reminders in Test Reports to Improve Guideline Compliance[NCT00414401] | 1,500 participants (Anticipated) | Interventional | 2001-05-31 | Completed | |||
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction[NCT00052026] | Phase 3 | 161 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| Photoplethysmography (PPG) to Predict Ejection Fraction and Other Echographic Data in the General Population[NCT04843371] | 200 participants (Actual) | Observational | 2021-08-20 | Completed | |||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate >90% is computed by arm and corresponding 95% confidence intervals are reported. (NCT02717507)
Timeframe: Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (Carvedilol) | 0.483 |
| Arm II (Placebo) | 0.517 |
Patients with toxicities reported via CTEP-AERS and all Grade ≥ 2 adverse events (AEs) that can be attributed probably or definitely to the study drug are considered to have AEs. The proportion of patients with AEs are reported by arm with corresponding 95% confidence intervals. (NCT02717507)
Timeframe: From baseline to month 24 since baseline
| Intervention | Proportion of patients with AE (Number) |
|---|---|
| Arm I (Carvedilol) | 0.0267 |
| Arm II (Placebo) | 0 |
"In a questionnaire, patients responded Yes/No to certain symptoms. If answered Yes, they selected slightly, moderately, quite a bit, or extremely regarding how bothersome the symptom was. The proportion of participants responding with any of these three categories was calculated by arm, and corresponding 95% confidence intervals are reported." (NCT02717507)
Timeframe: responses at days 14 to 730 were combined
| Intervention | Proportion of patients (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | Skin rash | Itchy skin | Dry Mouth | Easy bruising | Nosebleeds | Sunburn easily | Weight gain | Fluid retention | Swollen feet | Increased sweating | Feeling weak in parts of your body | Shortness of breath or wheezing | Chest pain or heaviness | Heart racing or skipping beats | Feeling shaky or having tremors | Decreased bodily movement | Feeling nervous | Feeling downhearted, sad, and/or tearful | Mood swings | Dizziness and/or lightheadedness | Dizziness upon standing (from sitting or lying down) | Insomnia | Difficulty concentrating | Interrupted sleep | Tendency to take naps | TiredwheezingFeeling unusually tired | Falling asleep at inappropriate times | Ringing in the ears | Difficulty breathing | Sensation that I have to urinate much of the time | Discoloration of urine (ie, bloody) | Decreased libido | Unusually heavy menstrual flows (N/A if postmenopausal or male) | |
| Arm I (Carvedilol) | 0.0533 | 0.0933 | 0.1467 | 0.0667 | 0.0133 | 0.0667 | 0.0933 | 0.0533 | 0.0267 | 0 | 0.0933 | 0.0933 | 0.0933 | 0.08 | 0.08 | 0.0533 | 0.0133 | 0.1467 | 0.2 | 0.12 | 0.16 | 0.1467 | 0.1733 | 0.1067 | 0.2 | 0.12 | 0.2267 | 0.0267 | 0.0533 | 0.0267 | 0.0667 | 0 | 0.0667 | 0.2 |
| Arm II (Placebo) | 0.1316 | 0.0789 | 0.1447 | 0.1711 | 0.0921 | 0.0526 | 0.0526 | 0.0789 | 0.0395 | 0.0921 | 0.0789 | 0.1316 | 0.0395 | 0.0921 | 0.0395 | 0.0789 | 0.0395 | 0.1711 | 0.1184 | 0.0921 | 0.1316 | 0.1579 | 0.1711 | 0.1316 | 0.2105 | 0.1053 | 0.2237 | 0.0395 | 0.0921 | 0 | 0.0789 | 0.0395 | 0.0526 | 0.111 |
A liver function measurement (in U/L). Normal range is 8-48 IU/L. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 29.122 | 28.014 | 30.148 | 27.196 | 29.86 |
| Arm II (Placebo) | 30.467 | 32.158 | 31.155 | 30.536 | 29.245 |
A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 26.608 | 24.068 | 25.426 | 24.375 | 24.561 |
| Arm II (Placebo) | 25.773 | 26.342 | 27.014 | 28.411 | 27.038 |
A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.5634 | 0.5973 | 0.563 | 0.593 | 0.5561 |
| Arm II (Placebo) | 0.4989 | 0.4942 | 0.4969 | 0.507 | 0.5449 |
N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 85.6301 | 90.7536 | 87.7167 | 99.4912 | 101.8333 |
| Arm II (Placebo) | 115.7222 | 128.9565 | 115.6364 | 93.2105 | 107.849 |
Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.00446 | 0.00265 | 0.00467 | 0.00737 | 0.01111 |
| Arm II (Placebo) | 0.0011 | 0.00174 | 0.00742 | 0.00684 | 0.01132 |
The percentage of blood leaving the heart at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | Percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 57.6 | 58.16 | 58.07 | 57.35 | 58.16 |
| Arm II (Placebo) | 57.42 | 56.84 | 56.61 | 57.6 | 57.5 |
A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 28.5362 | 28.5409 | 29.6121 | 27.8219 | 28.0302 |
| Arm II (Placebo) | 28.4339 | 27.6866 | 28.1085 | 27.8891 | 28.5953 |
A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 4.4464 | 4.3252 | 3.7345 | 3.4548 | 3.8073 |
| Arm II (Placebo) | 5.2538 | 4.3735 | 4.3415 | 4.0214 | 4.0791 |
The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 99.7507 | 99.3216 | 102.378 | 101.174 | 100.659 |
| Arm II (Placebo) | 93.3155 | 95.7434 | 96.5002 | 99.4656 | 98.9602 |
Thickness of cardiac muscle (in ml) of the left ventricle at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 4.5836 | 4.6035 | 4.636 | 4.6032 | 4.5147 |
| Arm II (Placebo) | 4.5269 | 4.565 | 0.0556 | 4.5462 | 4.5976 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | centimeter (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 03.2765 | 3.2901 | 3.262 | 3.32 | 3.2441 |
| Arm II (Placebo) | 3.2396 | 3.3023 | 3.2964 | 3.2798 | 3.286 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 42.2193 | 41.6128 | 42.8437 | 43.1453 | 42.0086 |
| Arm II (Placebo) | 39.7354 | 41.3839 | 41.8113 | 1.605 | 42.442 |
Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/cm^2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 93.2892 | 90.3088 | 88.984 | 93.9267 | 89.2513 |
| Arm II (Placebo) | 90.6135 | 96.8356 | 96.0616 | 91.6458 | 94.0647 |
The weight of the left ventricle adjusted for body surface area (in g/m2). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/m2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 57.4862 | 58.2839 | 60.2116 | 57.7053 | 58.3315 |
| Arm II (Placebo) | 57.9322 | 57.0924 | 59.4508 | 59.1793 | 59.1026 |
Z-score of the ratio of left ventricular (LV) posterior wall dimension of systole to internal LV dimension in diastole, calculated for each subject by subtracting the reference healthy population mean, then dividing by the standard deviation. The Z-score indicates the number of standard deviations away from the mean of the reference population. Negative Z- score indicates worse outcome. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | z-score (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | -0.1372 | -0.2167 | -0.2416 | -0.2375 | 0.0213 |
| Arm II (Placebo) | -0.0893 | 0.3215 | -0.2367 | -0.1974 | 0.1834 |
B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 27.3836 | 31.8406 | 26.8203 | 35.807 | 34.625 |
| Arm II (Placebo) | 31.4324 | 34.1857 | 33.2941 | 32.2807 | 33.3774 |
"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). Number shown for Unit of Measure refers to this ratio. Normal: >1. Impaired: <1. The mean is reported by arm at each timepoint with corresponding standard errors." (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ratio (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 1.728 | 1.642 | 1.723 | 1.732 | 1.603 |
| Arm II (Placebo) | 1.732 | 0.071 | 1.722 | 1.732 | 1.64 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
27 reviews available for carvedilol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl | 2022 |
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
Controlled-release carvedilol.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedi | 2008 |
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2008 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Ant | 2012 |
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2002 |
New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Humans; Myocardial I | 2003 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
Ventricular remodeling in heart failure and the effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Top | 2004 |
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2004 |
Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Topics: Adrenergic alpha-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Electrocardiography; Hea | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Echocardiography in the diagnosis and management of isolated left ventricular noncompaction: case reports and review of the literature.
Topics: Anticoagulants; Carbazoles; Cardiomyopathies; Carvedilol; Diagnosis, Differential; Echocardiography; | 2006 |
Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol.
Topics: Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Administration | 2006 |
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Carbazoles; Carvedilol; Delayed-Action Preparations; Eviden | 2007 |
Carvedilol in the treatment of elderly patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; C | 2008 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
Carvedilol in the failing heart.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; Propanolam | 2001 |
67 trials available for carvedilol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Dynamic Changes in the Molecular Signature of Adverse Left Ventricular Remodeling in Patients With Compensated and Decompensated Chronic Primary Mitral Regurgitation.
Topics: Adult; Cardiovascular Agents; Carvedilol; Chronic Disease; Gene Expression Profiling; Humans; Middle | 2019 |
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antineopla | 2017 |
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Topics: Adult; Antibiotics, Antineoplastic; Antioxidants; Carvedilol; Double-Blind Method; Doxorubicin; Fema | 2018 |
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted t
Topics: Adult; Antineoplastic Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Adminis | 2013 |
Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biomarkers; Carbazoles; Cardiomyopathy, Dilate | 2014 |
Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
Topics: Adrenergic alpha-1 Receptor Antagonists; Anthracyclines; Breast Neoplasms; Carbazoles; Carvedilol; D | 2014 |
Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Echocardiography; Female; Heart | 2015 |
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk
Topics: Adrenergic beta-Antagonists; Age Factors; Anthracyclines; Antibiotics, Antineoplastic; Carbazoles; C | 2016 |
Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Carbazoles; Cardiotonic Agents; Carvedil | 2016 |
Carvedilol reduces the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationsh | 2009 |
Usefulness of carvedilol to abolish myocardial postsystolic shortening in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Diastole; | 2009 |
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Blood Pressure; Carbazoles; Carvedilol; Female; Gen | 2010 |
Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol.
Topics: Adrenergic alpha-Antagonists; Carbazoles; Carvedilol; Child, Preschool; Diastole; Dose-Response Rela | 2010 |
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; E | 2011 |
CArdiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Carbazoles; Cardiac Resynchronization Therapy; Carved | 2011 |
Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
Topics: Antibiotics, Antineoplastic; Carbazoles; Carvedilol; Child; Child Welfare; Doxorubicin; Female; Huma | 2012 |
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blo
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Blood Pressure; | 2002 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Heart Failure; Hum | 2003 |
Use of 123I-MIBG scintigraphy to assess the impact of carvedilol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenergic alpha-Antagonists; Adrenergic Fibers; Carbazoles; Card | 2003 |
Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy.
Topics: 3-Iodobenzylguanidine; Adrenergic Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Car | 2003 |
Effects of carvedilol therapy on restrictive diastolic filling pattern in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; C | 2004 |
Gated myocardial SPECT to predict response to beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Bisoprolol; Carbazoles; Cardiomyopathy, Dilat | 2004 |
Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Humans; Male; Myoc | 2004 |
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Flow Velocity; Blood Pressure; Carbazole | 2004 |
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2004 |
Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Dou | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dobutamin | 2004 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Morbidity; M | 2004 |
Does carvedilol have antiarrhythmic properties?
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Follow-Up Studies; Humans | 2005 |
Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Heart Failure | 2005 |
The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carv | 2006 |
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Carbazoles; Carve | 2006 |
The effect of carvedilol therapy on myocardial functional reserve in patients with advanced heart failure caused by nonischemic dilated cardiomyopathy.
Topics: Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Heart; Heart Failure; Humans; Male; | 2006 |
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles | 2006 |
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; C | 2006 |
Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy.
Topics: Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Coronary Circulation; Double-Blind Method; Female; | 2007 |
[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Bisoprolol; | 2006 |
Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2007 |
Clinical reminders attached to echocardiography reports of patients with reduced left ventricular ejection fraction increase use of beta-blockers: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Echocardiography; Electronic Mail; Humans | 2007 |
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Disease-Free Survival; Female; | 2007 |
Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Comorbidity; Double-Blind Method; Female; Hu | 2007 |
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Chroni | 2007 |
Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Endothelin-1; Exercise; Exercise T | 2008 |
Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dizziness; Echocard | 1997 |
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Double-Blind Method; Heart | 1999 |
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiogra | 1999 |
Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, D | 1999 |
The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography, Doppler; | 2000 |
beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Female; Heart Failure; H | 2000 |
Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Echocardiography; Female | 2000 |
The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; E | 1999 |
Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Humans; Incidence; Myocard | 2000 |
Monitoring gas exchange during a constant work rate exercise in patients with left ventricular dysfunction treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Exercise Test; Female; Hum | 2000 |
CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; Humans; Myocardial Infarction; P | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra | 2001 |
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; He | 2001 |
Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
Topics: Adrenergic alpha-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method | 2001 |
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind | 2001 |
[Antioxidant and antiarrhythmic activity of carvedilol in patients with ischemic heart disease. Comparison with anaprilin].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Car | 2001 |
[Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction].
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Carbazoles; Carvedilol; Data Interpretat | 2001 |
Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; Heart | 2002 |
65 other studies available for carvedilol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Cardiotoxicity; Carved | 2020 |
Not the usual suspects: DRESS secondary to carvedilol.
Topics: Aged; Cardiovascular Agents; Carvedilol; Drug Hypersensitivity Syndrome; Female; Humans; New Zealand | 2020 |
Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Topics: Aged; Carbazoles; Cardiomyopathies; Carvedilol; Doxorubicin; Echocardiography; Female; Heart Failure | 2016 |
A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes.
Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cardiotonic Agents; Carvedilol; Cell | 2018 |
Clinical and echocardiographic outcome in patients receiving carvedilol for treatment of dilated cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Chi | 2013 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
Questions and answers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; | 2004 |
Cardioprotection during chemotherapy: need for faster transfer of knowledge from cardiology to oncology and role for a cardio-oncologist.
Topics: Antineoplastic Agents; Carbazoles; Carvedilol; Enalapril; Female; Hematologic Neoplasms; Humans; Mal | 2013 |
Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort St | 2013 |
Biventricular Takotsubo cardiomyopathy in Graves hyperthyroidism.
Topics: Adult; Carbazoles; Carvedilol; Drug Therapy, Combination; Electrocardiography; Female; Graves Diseas | 2014 |
Evaluation of global circumferential strain as prognostic marker after administration of β-blockers for dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Area Under Curve; Bisoprolol; Carbazoles; Cardiomyopathy, | 2014 |
Carvedilol reverses cardiac insufficiency in AKAP5 knockout mice by normalizing the activities of calcineurin and CaMKII.
Topics: A Kinase Anchor Proteins; Adrenergic Antagonists; Animals; Calcineurin; Calcium Signaling; Calcium-C | 2014 |
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Drug | 2015 |
Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention.
Topics: Animals; Aortic Valve Insufficiency; Carbazoles; Carvedilol; Chronic Disease; Echocardiography; Frac | 2015 |
Takotsubo cardiomyopathy after an emotional outburst.
Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Confli | 2015 |
Carvedilol-Enriched Cold Oxygenated Blood Cardioplegia Improves Left Ventricular Diastolic Function After Weaning From Cardiopulmonary Bypass.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiopul | 2016 |
Which factors predict the recovery of natural heart function after insertion of a left ventricular assist system?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles | 2008 |
Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Blood Flow Velocity; Carbazoles; Car | 2008 |
Severe left ventricular dysfunction in infants with ventricular preexcitation.
Topics: Adrenergic alpha-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilate | 2008 |
Isolated left ventricular hypertrabeculation/noncompaction in a Turner mosaic with male phenotype.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, | 2009 |
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carb | 2009 |
Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Apoptosis; Carbazoles; Cardiomyopathy, Dilate | 2010 |
Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart Failure, | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2010 |
Exercise-induced left bundle branch block and subsequent mechanical left ventricular dyssynchrony--resolved with pharmacological therapy.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bundle-Branch Block; Carbazoles; Carved | 2011 |
Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Echocardio | 2002 |
[Beta blockers in post-infarction state].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human | 2002 |
[Hormonal hyperactivity in heart failure. Differences in beta blockers].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Drug Therapy, Combina | 2002 |
Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-Up Stud | 2003 |
[When the left ventricle can no longer relax properly. Beta blocker improves diastolic function].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diastole; Humans; Myocardial Contraction; Propa | 2003 |
Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response | 2003 |
QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child Welfare; Child, Presch | 2003 |
[Heart failure symptoms despite normal pump function. Beta blockers also improve diastole].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Diastole; Echocardiog | 2003 |
Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carv | 2004 |
A comment on COMET: how to interpret a positive trial?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Europe; Heart | 2003 |
Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2004 |
The impact of baseline left ventricular size and mitral regurgitation on reverse left ventricular remodelling in response to carvedilol: size doesn't matter.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Chronic Disease; Echoc | 2004 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Huma | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz | 2005 |
Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Glucose; Carbazoles; Carvedilol; Dose-Response | 2005 |
Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dobutamine; Feasibili | 2005 |
Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; C | 2006 |
[Sudden cardiac death: prevention when is right! From evidence-based medicine to family-based medicine].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Death, Su | 2006 |
Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cholines | 2006 |
[Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Humans; Kidney Failure, Chronic; | 2006 |
Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Carbazoles; Carvedilol; Death; Disease-Free Survival; Drug Eva | 2006 |
Transient ischemic attack and electrocardiographic abnormalities revealing left ventricular noncompaction.
Topics: Acenocoumarol; Adult; Carbazoles; Carvedilol; Diagnosis, Differential; Electrocardiography; Heart Ve | 2007 |
Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Does the C-type natriuretic peptide have prognostic value in chagas disease and other dilated cardiomyopathies?
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Carbazoles | 2006 |
Unreliability of the %VO2 reserve versus %heart rate reserve relationship for aerobic effort relative intensity assessment in chronic heart failure patients on or off beta-blocking therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; Carvedi | 2007 |
Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
Topics: Adrenergic beta-Antagonists; Adult; Atrial Function, Left; Carbazoles; Cardiomyopathy, Dilated; Card | 2007 |
Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; C | 2007 |
Slowing the progression of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Contr | 1996 |
Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Hear | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilo | 2001 |
[Reversibility of left ventricular dysfunction in elderly patients with dilated cardiomyopathy undergoing treatment with carvedilol. Report of a case].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Cardiomyopathy, Dilated; Carvedilo | 2001 |
[CAPRICORN and COPERINUS studies].
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, Low; | 2002 |
[Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Humans; Muscular Dystrophy, | 2001 |
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Echocardiography; Echocardiography, | 2002 |
Left ventricular systolic dysfunction in a cardiac transplant recipient treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Transplantation; Humans; M | 2002 |